



COMMITTEE D02 on PETROLEUM PRODUCTS, LIQUID FUELS, AND LUBRICANTS

CHAIRMAN: Scott Fenwick, National Biodiesel Board, PO Box 104848, Jefferson City, MO 65110-4898, United States (800) 841-5849, Fax: (537) 635-7913, e-mail: sfenwick@biodiesel.org

FIRST VICE CHAIRMAN: Gregory C Miiller, Tannas Co, 4800 James Savage Rd, Midland, MI 48642, United States (989) 496-2309, Fax: (989) 496-3438, e-mail: gmiiller@savantgroup.com

SECOND VICE CHAIRMAN: James J Simnick, Bp Global Fuels Technology, 150 Warrenville Rd, BP Technology Center Mail Stop 603-2W, Naperville, IL 60563, United States (331) 702-4071, Fax: (630) 420-4831, e-mail: simnicij@bp.com

MEMBERSHIP SECRETARY: Ian P Mylrea, Stanhope-Seta, 70 Bramley Drive, Hampshire, RG27 8ZF, United Kingdom (193) 2 5-4589, e-mail: im@stanhope-seta.co.uk

STAFF MANAGER: Alyson Fick, (610) 832-9710, e-mail: afick@astm.org

VIE SP

Date: 20 July 22

ATTENDANCE

| | |
|------------------|--|
| SWRI | Christine Eickstead, Travis Kostan, Dan Engstrom |
| INTERTEK | Adrian Alfonso |
| LUBRIZOL | George Szappanos, Andrew Stevens |
| AFTON | Ben Maddock, Bob Campbell |
| ORONITE | Robert Stockwell, Jo Martinez |
| INFINEUM | Doyle Boese, |
| TMC | Rich Grundza |
| GM | Tim Cushing, Nathan Siebert, Aleise Jimenez |
| SHELL | Jeff Hsu |
| TEI | D. Lanctot |
| HCS GROUP | Izabela Gabrel |

MEETING:

Andrew Stevens is moving to a different position in Lubrizol. George is taking over the VIE test responsibilities. Andrew will retain the SP Chairmanship for the time being.

MOTION 1: Approve minutes from last call on 10 March 2022.

| | | | | | | | |
|------------------|---|---------------|---|------------------|---|-----------------|-----------|
| Proposed: | Andrew | | | | | | |
| Second: | Rich | | | | | | |
| Discussion: | None | | | | | | |
| Questions: | None | | | | | | |
| Votes: | <table border="0"> <tr> <td><i>Waive:</i></td> <td>0</td> </tr> <tr> <td><i>Negative:</i></td> <td>0</td> </tr> <tr> <td><i>Approve:</i></td> <td>Unanimous</td> </tr> </table> | <i>Waive:</i> | 0 | <i>Negative:</i> | 0 | <i>Approve:</i> | Unanimous |
| <i>Waive:</i> | 0 | | | | | | |
| <i>Negative:</i> | 0 | | | | | | |
| <i>Approve:</i> | Unanimous | | | | | | |

Outcome:

Rich presents data on the BL-6 prove-out matrix attached).

Stockwell would like the data presented differently – using 45 degree comparison charts.



Regarding outlier data points, the group will defer and final decision on this until the next meeting. Action: Labs to review internal data before next call.

During the last call, there was a negative vote on an Information Letter. The reasoning behind the vote was deemed not relevant to the issue at hand, but the concern still needs to be addressed.

CUSUMS: one of the biggest drivers in the shape of the CUSUM is lab differences. The CUSUMS show periods of levelling out (which reflect the test being on target). No one reference oil (RO) fully accounts for these periods.

From the meeting invite:

Our most recent CUSUM plots are copied below. These plots “add up” the severity of reference results over time. The general goal is that these bounce around zero. You can see that ours have moved steadily severe over time. The purpose of the call is to begin the discussion regarding how we need to deal with this situation. If there are any questions before the meeting, please let me know.



Doyle – Most of the data before 2018 does not include a correction factor (CF). CF included after. Rich – yes.

Adrian – looks like end of Q3 and all of Q4 – almost a seasonal effect? Could be due to activity? Rich – could be, but even in those times, see a completely different mix of stands. Switch between VIE and VIF....

Travis – one of the first steps we should do with any of these issues, start with what we know. Lab distributions, stand activity, RO distribution, etc. Is it consistent across these areas or are there areas that stick out. Rich – there are some lab differences, and one RO, 544, is closer to target than the other two ROs.

Rich – addition of the CF did skew the use of ROs.

Andrew – develop a task force (TF) to study the VIE severity to do a deep technical dive into this (as opposed to doing this in the SP setting). Then bring findings and recommendations for further actions to address this issue. Rich – remember, we did this same thing in 2018. Andrew – yes.

Group – no response. Andrew – silence = agreement. We shall form a VIE severity task force to study this issue in more detail and bring recommendations to the panel. Volunteer to lead the TF? Adrian – I will do it. Andrew – we should cover both the VIE and VIF in this TF. Group – agreed.

Adrian – will send an email to the SP distribution list asking for volunteers to participate in the TF. Needs to include statisticians.

Robert – if look at CUSUM, the test has been pretty stable for the past several years. Is the objective of the TF for the CUSUM to go back to zero? Andrew – that is the general goal.... Doyle – actually the goal is it to remain at a constant level, not necessarily zero.

Travis – not a fan of CUSUMS, tend to exaggerate problems, and are difficult to interpret. Prefer EWMA charts when discussing severity.

Bob – the overall question is, do we let the SAs take care of the test bias, or do we need a bigger lever?

Adrian – will send out communication on TF meeting schedule.

Meeting time up, meeting adjourned.